Newron Pharmaceuticals Successfully Completes Pilot Study of Safinamide in Restless Legs Syndrome
Newron Pharmaceuticals SpA, a research and development company focused on novel CNS therapies, announced that treatment with its investigational new drug, safinamide, resulted in a significant improvement in all efficacy parameters studied when administered to patients with restless legs syndrome (RLS). Safinamide was also found to be well tolerated and did not exhibit any clinically relevant side-effects. RLS is a neurological disorder, characterized by jerky movements of the lower extremities which appear mostly in the evening and during sleep.
RLS is a growing neurological condition affecting approximately 5% of the adult population in the US and EU. It is characterized by jerky movements or an uncomfortable, often painful, sensation in the lower extremities that mostly appear in the evening, at rest and during sleep. RLS is commonly associated with frequent awakenings at night and somnolence during the day, thus negatively affecting a patient's quality of life. In many cases, RLS can lead to bouts of depression and in some, suicide.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
